雾化吸入布地奈德和泼尼松龙静脉用药治疗老年COPD急性加重期的对比研究被引量：16

下载PDF

导出

摘要目的观察布地奈德雾化吸入对比静脉用甲基泼尼松龙治疗老年慢性阻塞性肺病(COPD)急性加重期的疗效、安全性和经济成本。方法60例老年中重度COPD急性加重期患者随机分为布地奈德组(28例)和泼尼松龙组(32例),分别给予布地奈德混悬液雾化吸入2mg/次(1次/6h)和甲基泼尼松龙静滴40mg/次(每天1次),其他治疗相同。记录治疗后第1、3、5、10d临床症状评分和FEV1/预计值、PO2、PCO2、副反应和成本费用。结果①治疗后10dSGRQ生活质量评分布地奈德组下降了9.8分(P<0.05),泼尼松龙组下降11.4分(P<0.05),两组间差异无统计学意义。②治疗后10dFEV1/预计值布地奈德组和泼尼松龙组分别上升了6.72%和8.30%(P<0.05)(1mmHg=0.1333kPa),PaO2分别上升7.0mmHg和8.0mmHg(P<0.05),PaCO2分别下降7.3mmHg和8.1mmHg(P<0.05)。③短期副反应布地奈德组主要为声嘶,泼尼松龙组为血糖升高及消化道出血。④两组患者住院时间,需要辅助通气的比例,成本费用差异均无统计学意义。结论大剂量布地奈德雾化吸入治疗老年中重度COPD急性加重期与静脉用泼尼松龙疗效一致,全身副反应减轻,短期治疗费用无明显增加。

作者舒德芬杨中华张艳玲吴红梅董碧蓉

机构地区四川大学华西医院老年科

出处《四川大学学报（医学版）》 CAS CSCD 北大核心 2009年第1期172-174,共3页 Journal of Sichuan University(Medical Sciences)

关键词慢性阻塞性肺病布地奈德泼尼松龙

分类号 R563.9 [医药卫生—呼吸系统]

引文网络
相关文献

参考文献9

1Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/ WHO Workshop report. 2004.
2Wilson CB, Jones PW, O'Leary CJ, et al. Validation of the St.George's Respiratory Questionnaire in Bronchiectasis, Am J Respir Crit Care Med,1997,156(2):536-541.
3McEvoy CE, Niewoehner DE. Adverse effects of corticosteroid therapy for COPD. A critical review. Chest,1997,111(3):732- 743.
4Yang IA, Fong K, Sim EH, et al. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2007,2[2007-06-15]. http://mrw. interscience. wiley, com/cochrane/clsysrev/articles/CD002991/frame, html
5Mirici A, Meral M, Akgun M. Comparison of the efficacy of nebulised budesonide with parenteral corticosteroids in the treatment of acute exaeerbatlons of chronic obstructive pulmonary disease. Clinical Drug Investigation,2003,23(1):55-62.
6Gartlehner G, Hansen RA, Carson SS, et al. Efficacy and safety of inhaled corticosteroids in patients with COPD:a systematic review and Meta-analysis of health outcomes. Ann Fam Med, 2006,4(3):253-262.
7Hattotuwa KL, Gizyeki MJ, Ansari TW, et al. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med,2002,165(12) :1592-1596.
8Verheggen MM, Adriaansen-Soeting PW, Berrevoets CA. Glucocortieoid receptor expression in human bronchial epithelial cells: effects of smoking and COPD. Mediators Inflamm, 1998 ; 7 (4) :275-281.
9Foster JM, Aucott L, van der Werf RH, et al. Higher patient perceived side effects related to higher daily doses of inhaled corticosteroids in the community: a cross-sectional analysis. Respir Med, 2006,100(8) : 1318-1336.